Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934906 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL29457703 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL6933968 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL6557492 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL4575410 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL232128 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL232384 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL232385 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL12019442 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL232127 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | ENTA HOLDING LLC | 2008-08-14 | — | — | US | disclosed |
| US-20050255151-A1 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds | ENTA HOLDING LLC | 2005-11-17 | — | — | US | disclosed |
| US-6919350-B2 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-6300332-B1 | DRUG MEDIATED RESPIRATORY DEPRESSION, MUSCLE RIGIDITY AND NAUSEA/VOMITING AND SIDE EFFECT REDUCTION | DELTA PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050255151-A1 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds | OPRD1, OPRM1, OPRK1 | CYP3A4 866/4885CYP1A2 751/4885OPRD1 1/4885 |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP3A4 866/4885CYP1A2 751/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.